Privileged Scaffolds for Drug Design and Activity Improvement-Part I

Yongtao       Duan; Hai-liang       Zhu

[1] 
Huang, H.; Song, C.; Chang, J. Synthesis and biological activity study of tanshinone derivatives: a literature and patent review. Curr. Top. Med. Chem.,  2020, 20(28), 2520-2534.
[2] 
Zhang, Z.; Shu, B.; Zhang, Y.; Deora, G.S.; Li, Q-S. 2,4,5-Trisubstituted thiazole: a privileged scaffold in drug design and activity improvement. Curr. Top. Med. Chem.,  2020, 20(28), 2535-2577.
[3] 
Xu, C.; Fang, M-Y.; Wang, K.; Liu, J.; Tai, G-P.; Zhang, Z-T.; Ruan, B-F. Discovery and development of inflammatory inhibitors from 2-phenylchromonone (flavone) scaffolds. Curr. Top. Med. Chem.,  2020, 20(28), 2578-2598.
[4] 
Mao, Y.; Soni, K.; Sangani, C.; Yao, Y. An overview of privileged scaffold: quinolines and isoquinolines in medicinal chemistry as anticancer agents. Curr. Top. Med. Chem.,  2020, 20(28), 2599-2633.
[5] 
Li, D-D.; Yu, P.; Xiao, W.; Wang, Z-Z.; Zhao, L-G. Berberine: a promising natural isoquinoline alkaloid for development of hypolipidemic drug. Curr. Top. Med. Chem.,  2020, 20(28), 2634-2647.

Download Options

Rights & Permissions Print Cite

Current Topics in Medicinal Chemistry

Title:Privileged Scaffolds for Drug Design and Activity Improvement-Part I

Volume: 20 Issue: 28

Author(s): Yongtao Duan and Hai-liang Zhu

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Duan Yongtao and Zhu Hai-liang , Privileged Scaffolds for Drug Design and Activity Improvement-Part I, Current Topics in Medicinal Chemistry 2020; 20 (28) . https://dx.doi.org/10.2174/156802662028201021110151

DOI https://dx.doi.org/10.2174/156802662028201021110151	Print ISSN 1568-0266
Publisher Name Bentham Science Publisher	Online ISSN 1873-4294

About this journal

Call for Papers in Thematic Issues

Submission closes on : 24 September, 2024

Chemistry Based on Natural Products for Therapeutic Purposes

The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more

Guest Editor(s): Dr. Parag Jain

Submission closes on : 28 July, 2024

Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design

Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more

Guest Editor(s): Dr. Igor J. Dos Santos Nascimento

Submission closes on : 13 August, 2024

Drug Discovery in the Age of Artificial Intelligence

In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more

Guest Editor(s): Dr. Liangxu Xie

Submission closes on : 31 December, 2024

From Biodiversity to Chemical Diversity: Focus of Flavonoids

Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more

Guest Editor(s): Dr. Marcello Iriti